Organon & Co. (NYSE:OGN) Posts Earnings Results, Misses Expectations By $0.09 EPS

Organon & Co. (NYSE:OGN) released its earnings results on Thursday. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09), Zacks reports. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Price Performance

Shares of NYSE OGN traded up $1.27 during midday trading on Thursday, reaching $15.97. The company’s stock had a trading volume of 6,160,096 shares, compared to its average volume of 2,694,525. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company has a 50 day moving average price of $15.33 and a 200 day moving average price of $17.54. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market cap of $4.11 billion, a price-to-earnings ratio of 3.17, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76.

Analyst Ratings Changes

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.